Health Condition 1: C50- Malignant neoplasm of breast
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Tata Memorial Centre, Mumbai
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically proven breast primary 2. All breast cancer patients older than 18 years of age 3. Able to understand and provide consent 4. All such women that fit into the following disease definitions: a. Synchronous Oligometastases would be defined as up to 5 sites and not necessarily in the same organ as per the Advanced breast cancer 4 guideline. All of these sites should be amenable for treatment with locally ablative therapy. The disease is considered synchronous when it is diagnosed within 3 months of completing therapy for cancer for eg. Within 3 months of completing locoregional radiotherapy (Not accounting for any maintenance systemic therapy like hormonal therapy). b. Metachronous Oligometastases (also referred to as Oligorecurrence) would be defined as up to 5 sites of distant metastases detected 3 months after completion of treatments for breast cancer such as surgery, chemotherapy and radiation therapy. c. Oligoprogression would be defined as progression of disease seen in up to 5 sites while other sites are controlled/ stable defined by imaging and clinical characteristics. d. Oligopersistance would be defined as persistent disease in up to 5 sites post completion of all planned treatment while other sites of metastases should be controlled or stable based on the imaging and clinical characteristics.
Exclusion criteria
Exclusion criteria: 1. Patients whose medical records are not available
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Incidence of oligometastases, Oligorecurrence, Oligoprogression & Oligopersistence in breast cancer patients 2.Recording patterns of treatment of the metastatic siteTimepoint: Year-wise incidence of oligometastases, Oligorecurrence, Oligoprogression & Oligopersistence in breast cancer patients from 2017 2.Recording patterns of treatment of the metastatic site | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Incidence of acute & late toxicity from the treatment of the metastatic site 2.Local control of the treated metastatic site based on clinical & imaging characteristics 3.Progression free survival & 4.Patterns of recurrence/ disease progression 5.Overall survival (Death due to any cause) 6.Treatment related deaths 7.Evaluation of prognostic factors predicting better outcomes 8.Correlation of dosimetric parameters with acute and late toxicity scored using EORTC grading system v 4.0 9.Comparison of Local control, disease free survival and overall survival with the historical cohort of oligometastatic patients treated at Tata Memorial Centre 10.Establish Quality indicators for the institute based on the local control and toxicity data collectedTimepoint: Survival end points at 1,2,3 & 5 years since diagnosis | — |
Countries
India
Contacts
Public ContactDr Rima Sanjay Pathak
Tata Memorial Hospital
Outcome results
None listed